Literature DB >> 3054002

Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study.

U Tirelli1, V Zagonel, D Serraino, J Thomas, B Hoerni, A Tangury, U Ruhl, P Bey, N Tubiana, W P Breed.   

Abstract

The results of a European Organization for Research and Treatment of Cancer (EORTC) retrospective study on non-Hodgkin's lymphoma (NHL) in elderly patients (greater than or equal to 70 years of age) seen in Europe in 1984 are reported. A precodified form was sent to 55 European institutes in order to evaluate the incidence of NHL in the elderly with regard to natural history, treatment-related toxicity, response, and survival. Thirteen institutes participated in the study. One hundred thirty-seven cases of NHL were observed in the elderly during 1984, making up 28% of the total number of NHL seen in those institutes. The median age was 77 years; 21% of the patients had favorable (low-grade) and 73% unfavorable (intermediate- and high-grade) histology, according to the Working Formulation. Stage at presentation was localized (I and II) in 60% and advanced in 37% of the patients. Most of the physicians used standard therapy regimens at reduced doses, from the beginning of the treatment. Sixty patients (44%) underwent a "conservative" treatment (one or two antineoplastic drugs or local field radiotherapy) and 77 (56%) an "aggressive" treatment (polychemotherapy regimens or extended field radiotherapy). Response was similar between the two treatment groups, but severe and lethal toxicity was significantly higher among patients treated with aggressive therapy. Prospective randomized studies are clearly needed to define the optimal treatment in elderly patients with advanced unfavorable NHL.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3054002     DOI: 10.1200/JCO.1988.6.11.1708

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

Review 1.  Palliative therapies in elderly cancer patients.

Authors:  F Porzsolt; J Zeeh; D Platt
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

2.  Prognosis of infections in elderly patients with haematological diseases.

Authors:  F Rossini
Journal:  Support Care Cancer       Date:  1996-01       Impact factor: 3.603

3.  Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Iwona Skoneczna; Sandrine Marreaud; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

4.  Cancer chemotherapy in the elderly: a series of 51 patients aged greater than 70 years.

Authors:  Y Bécouarn; B N Bui; R Brunet; A Ravaud
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  Potential role of oral anthracyclines in older patients with cancer.

Authors:  W S Lasota; D L de Valeriola; M J Piccart
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

6.  Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness.

Authors:  Linda S Elting; Ying Xu; Mariana Chavez-MacGregor; Sharon H Giordano
Journal:  Support Care Cancer       Date:  2016-01-21       Impact factor: 3.603

Review 7.  The aged patient with lung cancer. Management recommendations.

Authors:  V Zagonel; U Tirelli; D Serraino; G Lo Re; M C Merola; M Mascarin; M G Trovò; A Carbone; S Monfardini
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

Review 8.  Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.

Authors:  Yun Hwa Jung; In Sook Woo; Chi Wha Han
Journal:  Korean J Intern Med       Date:  2015-08-27       Impact factor: 2.884

9.  Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.

Authors:  J H Youngson; J M Jones; J G Chang; M Harris; S S Banergee
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.